Neowater(TM)-based products consist of largely hydrated nano-particles that lead to several important benefits for research, diagnostics and bio-pharma applications. The hydrated nano-particles, like non-ionic detergent derived micelles, reduce the entropy of aqueous solutions and mimic intracellular water. In addition, by design, they exhibit hydrophobic properties.

The non-ionic Neowater^TM works by coating components at their molecular level, thus exposing, increasing and/or enhancing those specific surfaces which are required for a specific reaction but are normally not available to interact (e.g. GC-rich DNA). Therefore, very small volumes of Neowater^TM, and reduced component's concentrations or amounts, are needed for a reaction when using Neowater^TM. Neowater^TM allows for (low-volume) miniaturization of Life Sciences products, applications and processes.
Neowater^TM-based products significantly accelerate and improve the efficiency of biological reactions.

The partnership program leverages the inherent advantages of Do-Coop's Nano-technology, Neowater^TM, by enabling well-established Life Sciences industry players to dramatically enhance their already successful product lines to the benefit of their customers.

"Our recent research has indicated that there are critical roadblocks preventing significant advances in research, diagnostics and therapeutics in the bio-pharma industry. As an example, despite the impressive advances in genetic-based therapeutics research, there is still a large, still unbridgeable gap to translate these initial R&D achievements into viable, commercial products that will one day cure human diseases at their genetic root.

"Furthermore, our research uncovered that if the Life Sciences industry is to achieve a breakthrough jump in price-performance, as recently seen in the Microelectronics industry, there is an urgent need to drive miniaturization of biological reactions.

"This is what the entire Life Sciences industry has been expecting for a long time, and hoping that Nano-technology would be the awaited solution to address and solve these urgent needs.

"Neowater^TM nano-technology, combined with our partners' existing products and processes, allows the Life Science industry to deliver on their promise of genetic-based therapeutics, and for Nano-technology to become the key that unlocks the previously closed door to miniaturization in the Life Sciences industry. Neowater^TM will turn our partner's offering from ordinary into extraordinary," said Eran Gabbai, founder and CTO of Do-Coop Technologies, and the inventor of Neowater^TM.

Neowater^TM Nano-technology has been identified and recognized by Frost & Sullivan. Do-Coop received the Frost & Sullivan's coveted "2004 Enabling Technology in Nano-medicine" award, and will be receiving Frost & Sullivan's "2005 Excellence in Medicine Award" this week in London.